A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 57; no. 9; pp. 2232 - 2234
Main Authors Townsend, William, Johnson, Rod J., Pottinger, Bryson T., Counsell, Nicholas, Smith, Paul, Chadwick, Humra, Evans, Katy, Wickham, Caroline, Rudin, Claudius E
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.09.2016
Subjects
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cyclophosphamide - administration & dosage
Cyclophosphamide - adverse effects
Disease Progression
Drug Administration Schedule
Female
Humans
Immunoblastic Lymphadenopathy - drug therapy
Immunoblastic Lymphadenopathy - mortality
Immunoblastic Lymphadenopathy - pathology
Lymphoma, T-Cell - drug therapy
Lymphoma, T-Cell - mortality
Lymphoma, T-Cell - pathology
Male
Middle Aged
Survival Analysis
Thalidomide - administration & dosage
Thalidomide - adverse effects
Vidarabine - administration & dosage
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
Online AccessGet full text

Cover

More Information
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2015.1133814